Radionetics Oncology taps de Silva as CEO

By staff writers

April 12, 2022 -- Pharmaceutical firm Radionetics Oncology has named Dr. Nishan de Silva as CEO and a director of the company's board. De Silva most recently was with AFYX Therapeutics.

De Silva led a phase 2 clinical trial program for a sponsor-conducted study in oral lichen planus while at AFYX Therapeutics. Before heading AFYX Therapeutics, de Silva served as president and chief operating officer of Poseida Therapeutics, a gene therapy and gene editing therapeutics-focused company.

Radionetics Oncology is focused on the discovery and development of radiotherapeutics for the treatment of a wide range of oncology indications. The company has added eight new members to its management team since it launched in October 2021.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking